Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Loyola gastroenterologist provides tips to IBS patients for healthy living

More than 20 percent of the US population lives with irritable bowel syndrome (IBS) and for many Americans it is an ongoing challenge. But when it comes to treatment, old advice from Mom was right. Often, the key is to eat right and go outside and play.

16 Oct 2015

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Laboratories, LLC ("Commonwealth") announced today that it has formed an agreement with Quest Diagnostics ("Quest") that will expand the availability of IBSchek™, a new laboratory developed blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS).

From Quest Diagnostics 15 Oct 2015

Study evaluates effectiveness of hypnotherapy

Although hypnosis has existed for hundreds of years, today it is still difficult to clearly judge its usefulness in the medical domain.

10 Sep 2015

GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

The protein glycomacropeptide (GMP) is derived from whey, the liquid by-product of the cheese-making process. GMP contains low amounts of the amino acid phenylalanine. Individuals who suffer from phenylketonuria—a metabolic disorder that causes cognitive impairment when phenylalanine level is too high—can use GMP as an alternative protein source. GMP supplementation has also been observed to improve gastrointestinal health by protecting the digestive system from pathogens and by having an anti-inflammatory effect.

20 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Researchers at Sheffield Teaching Hospitals have received awards for their work investigating coeliac disease and irritable bowel syndrome, two common gastrointestinal conditions.

10 Aug 2015

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information.

24 Jul 2015

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

The relationship between mental and physical health is well established. But when mental and physical illnesses co-occur, patients' accounts of physical illness are sometimes arbitrarily discredited or dismissed by physicians.

10 Jul 2015

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients.

2 Jul 2015

Study provides insights into the cause of irritable bowel syndrome

A team comprised of scientists at VIB, KU Leuven and UZ Leuven has made significant progress in uncovering the connection between psychological factors and the immune system. Their findings are based on an investigation of a massive drinking water contamination incident in Belgium in 2010, and are now published in the leading international medical journal Gut.

2 Jul 2015

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Jun 2015

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).

29 Jun 2015

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX.

25 Jun 2015

A gastroenterologist guide to probiotics

In recent years, scientists have introduced us to a paradigm shift in the microscopic world. We've moved from thinking about all bacteria as bad guys to be wiped out with antibiotics and hand sanitizer to recognizing that some microbes are helpers, good bacteria that live in our GI tract (and all over our bodies) that keep us healthy.

11 Jun 2015

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Loyola gastroenterologist provides tips to IBS patients for healthy living

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Study evaluates effectiveness of hypnotherapy

GMP protein can improve gastrointestinal health by protecting digestive system from pathogens

Ardelyx reports net income of $9.0 million for second quarter 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Sheffield researchers win national awards for pioneering work on coeliac disease, IBS

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

Study demonstrates the important role of placebo effect in medical care

Study provides insights into the cause of irritable bowel syndrome

Pinaverium offers quick relief from IBS symptoms

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

A gastroenterologist guide to probiotics

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Newsletters you may be interested in